Abstract
Hypertension is traditionally considered a disease in which elevated blood pressure contributes to inflammation and activation of the immune system, leading to cardiovascular injury and end-organ damage. Here, we discuss the effects of aldosterone on the immune system and aldosterone’s contribution to vascular pathogenesis. Studies in human have suggested a broader role for aldosterone, beyond elevating blood pressure. Recent clinical data support the notion that aldosterone can directly alter the function of the immune system and cause vascular-damaging inflammation. Clinical observations have been reproduced in experimental models of hypertension, further supporting the idea that an aberrant immune response contributes to the onset of hypertension. Such studies have shown that myeloid cells are required to induce the disease and IL-17-producing CD4+ T cells may contribute to maintaining aldosterone-mediated hypertension. In addition, regulatory T cells diminish the inflammatory damage caused by aldosterone during hypertension. This is a very active area of research that could lead to new therapeutic targets for treating hypertension.
Keywords: Aldosterone, GPR30, hypertension, inflammation, mineralocorticoid receptor.
Current Molecular Medicine
Title:Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage
Volume: 13 Issue: 6
Author(s): N. Munoz-Durango, M.F. Barake, N.A. Letelier, C. Campino, C.E. Fardella and A.M. Kalergis
Affiliation:
Keywords: Aldosterone, GPR30, hypertension, inflammation, mineralocorticoid receptor.
Abstract: Hypertension is traditionally considered a disease in which elevated blood pressure contributes to inflammation and activation of the immune system, leading to cardiovascular injury and end-organ damage. Here, we discuss the effects of aldosterone on the immune system and aldosterone’s contribution to vascular pathogenesis. Studies in human have suggested a broader role for aldosterone, beyond elevating blood pressure. Recent clinical data support the notion that aldosterone can directly alter the function of the immune system and cause vascular-damaging inflammation. Clinical observations have been reproduced in experimental models of hypertension, further supporting the idea that an aberrant immune response contributes to the onset of hypertension. Such studies have shown that myeloid cells are required to induce the disease and IL-17-producing CD4+ T cells may contribute to maintaining aldosterone-mediated hypertension. In addition, regulatory T cells diminish the inflammatory damage caused by aldosterone during hypertension. This is a very active area of research that could lead to new therapeutic targets for treating hypertension.
Export Options
About this article
Cite this article as:
Munoz-Durango N., Barake M.F., Letelier N.A., Campino C., Fardella C.E. and Kalergis A.M., Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage, Current Molecular Medicine 2013; 13 (6) . https://dx.doi.org/10.2174/1566524011313060015
DOI https://dx.doi.org/10.2174/1566524011313060015 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Low Levels of High Density Lipoprotein Increase the Severity of Cerebral White Matter Changes:Implications for Prevention and Treatment of Cerebrovascular Diseases
Current Alzheimer Research L-4F Differentially Alters Plasma Levels of Oxidized Fatty Acids Resulting in more Anti-Inflammatory HDL in Mice
Drug Metabolism Letters Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol
Current Drug Metabolism Metabolic Syndrome the Gynecologist’s Approach
Current Women`s Health Reviews Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry Gonadal Hormones in Adolescent Females with β-Thalassemia in Relation to Iron Load
Endocrine, Metabolic & Immune Disorders - Drug Targets Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase
Current Medicinal Chemistry Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Preeclampsia – Aetiopathogenesis and Clinical Management
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: The Life Cycle of the Heart Failure Patient)
Current Cardiology Reviews Editorial from Editor-in-Chief (Adherence to CPAP: Understanding the Key to a Successful Treatment)
Current Respiratory Medicine Reviews TRH/TRH-R1 Receptor Signaling in the Brain Medulla as a Pathway of Vagally Mediated Gut Responses During the Cephalic Phase
Current Pharmaceutical Design Metabolic Syndrome During Menopause
Current Vascular Pharmacology Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Vitamin D in Chronic Kidney Disease: New Potential for Intervention
Current Drug Targets Is the Hepatic Factor a miRNA that Maintains the Integrity of Pulmonary Microvasculature by Inhibiting the Vascular Endothelial Growth Factor?
Current Cardiology Reviews Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Canagliflozin : A New Hope in the Antidiabetic Armamentarium
Recent Patents on Cardiovascular Drug Discovery The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications
Current Medicinal Chemistry Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition
Current Drug Targets